The Hippo signalling pathway and its implications in human health and diseases
Tóm tắt
As an evolutionarily conserved signalling network, the Hippo pathway plays a crucial role in the regulation of numerous biological processes. Thus, substantial efforts have been made to understand the upstream signals that influence the activity of the Hippo pathway, as well as its physiological functions, such as cell proliferation and differentiation, organ growth, embryogenesis, and tissue regeneration/wound healing. However, dysregulation of the Hippo pathway can cause a variety of diseases, including cancer, eye diseases, cardiac diseases, pulmonary diseases, renal diseases, hepatic diseases, and immune dysfunction. Therefore, therapeutic strategies that target dysregulated Hippo components might be promising approaches for the treatment of a wide spectrum of diseases. Here, we review the key components and upstream signals of the Hippo pathway, as well as the critical physiological functions controlled by the Hippo pathway. Additionally, diseases associated with alterations in the Hippo pathway and potential therapies targeting Hippo components will be discussed.
Từ khóa
Tài liệu tham khảo
Cheng, J., Wang, S., Dong, Y. & Yuan, Z. The role and regulatory mechanism of Hippo signaling components in the neuronal system. Front. Immunol. 11, 281 (2020).
Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246–257 (2013).
Yu, F. X. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780–791 (2012).
Misra, J. R. & Irvine, K. D. The Hippo signaling network and its biological functions. Annu. Rev. Genet. 52, 65–87 (2018).
Calses, P. C., Crawford, J. J., Lill, J. R. & Dey, A. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer 5, 297–307 (2019).
Dey, A., Varelas, X. & Guan, K. L. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat. Rev. Drug Discov. 19, 480–494 (2020).
Zhu, J. Y., Lin, S. & Ye, J. YAP and TAZ, the conductors that orchestrate eye development, homeostasis, and disease. J. Cell. Physiol. 234, 246–258 (2018).
Lee, M., Goraya, N., Kim, S. & Cho, S. H. Hippo-YAP signaling in ocular development and disease. Dev. Dyn. 247, 794–806 (2018).
Wang, J., Liu, S., Heallen, T. & Martin, J. F. The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nat. Rev. Cardiol. 15, 672–684 (2018).
Austin, K. M. et al. Molecular mechanisms of arrhythmogenic cardiomyopathy. Nat. Rev. Cardiol. 16, 519–537 (2019).
Sun, M. et al. New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis. Pharm. Res. 169, 105635 (2021).
Chanda, D. et al. Developmental pathways in the pathogenesis of lung fibrosis. Mol. Asp. Med. 65, 56–69 (2019).
Russell, J. O. & Camargo, F. D. Hippo signalling in the liver: role in development, regeneration and disease. Nat. Rev. Gastroenterol. Hepatol. 19, 297–312 (2022).
Driskill, J. H. & Pan, D. The Hippo pathway in liver homeostasis and pathophysiology. Annu. Rev. Pathol. 16, 299–322 (2021).
Hong, L. et al. Role of Hippo signaling in regulating immunity. Cell. Mol. Immunol. 15, 1003–1009 (2018).
Zhang, Y., Zhang, H. & Zhao, B. Hippo signaling in the immune system. Trends Biochem. Sci. 43, 77–80 (2018).
Ma, S., Meng, Z., Chen, R. & Guan, K. L. The Hippo pathway: biology and pathophysiology. Annu. Rev. Biochem. 88, 577–604 (2019).
Piccolo, S., Dupont, S. & Cordenonsi, M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol. Rev. 94, 1287–1312 (2014).
Rausch, V. & Hansen, C. G. The Hippo pathway, YAP/TAZ, and the plasma membrane. Trends Cell Biol. 30, 32–48 (2020).
Bae, S. J. et al. SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK. Elife 6, e30278 (2017).
Ribeiro, P. S. et al. Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling. Mol. Cell 39, 521–534 (2010).
Zheng, Y. & Pan, D. The Hippo signaling pathway in development and disease. Dev. Cell 50, 264–282 (2019).
Chen, R. et al. STRIPAK integrates upstream signals to initiate the Hippo kinase cascade. Nat. Cell Biol. 21, 1565–1577 (2019).
Yin, F. et al. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 154, 1342–1355 (2013).
Yu, F. X. & Guan, K. L. The Hippo pathway: regulators and regulations. Genes Dev. 27, 355–371 (2013).
Chan, E. H. et al. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24, 2076–2086 (2005).
Qi, S. et al. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Mol. Cell 82, 1850–1864 (2022).
Li, Q. et al. The conserved Misshapen–Warts–Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in. Drosoph. Dev. Cell 31, 291–304 (2014).
Li, S. et al. Overlapping functions of the MAP4K family kinases Hppy and Msn in Hippo signaling. Cell Discov. 1, 15038 (2015).
Meng, Z. et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat. Commun. 6, 8357 (2015).
Zheng, Y. et al. Identification of Happyhour/MAP4K as alternative Hpo/Mst-like kinases in the Hippo kinase cascade. Dev. Cell 34, 642–655 (2015).
Plouffe, S. W. et al. Characterization of Hippo pathway components by gene inactivation. Mol. Cell 64, 993–1008 (2016).
Wei, X., Shimizu, T. & Lai, Z. C. Mob as tumor suppressor is activated by Hippo kinase for growth inhibition in. Drosoph. EMBO J. 26, 1772–1781 (2007).
Praskova, M., Xia, F. & Avruch, J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr. Biol. 18, 311–321 (2008).
Oka, T., Mazack, V. & Sudol, M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J. Biol. Chem. 283, 27534–27546 (2008).
Hao, Y. et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 283, 5496–5509 (2008).
Moroishi, T. et al. The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell 167, 1525–1539e1517 (2016).
Pocaterra, A., Romani, P. & Dupont, S. YAP/TAZ functions and their regulation at a glance. J. Cell Sci. 133, jcs230425 (2020).
Ma, S. et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER(+) breast cancer. Nat. Commun. 13, 1061 (2022).
Jiao, S. et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25, 166–180 (2014).
Zhang, W. et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP–TEAD transcriptional complex. Cell Res. 24, 331–343 (2014).
Lin, K. C., Park, H. W. & Guan, K.-L. Regulation of the Hippo pathway transcription factor TEAD. Trends Biochem. Sci. 42, 862–872 (2017).
Guo, T. et al. A novel partner of Scalloped regulates Hippo signaling via antagonizing Scalloped-Yorkie activity. Cell Res. 23, 1201–1214 (2013).
Koontz, L. M. et al. The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev. Cell 25, 388–401 (2013).
Maejima, Y., Zablocki, D., Nah, J. & Sadoshima, J. The role of the Hippo pathway in autophagy in the heart. Cardiovasc. Res. cvac014 (2022).
Tian, Q. et al. RICH1 inhibits breast cancer stem cell traits through activating kinases cascade of Hippo signaling by competing with Merlin for binding to Amot-p80. Cell Death Dis. 13, 71 (2022).
Guo, Y. et al. Context-dependent transcriptional regulations of YAP/TAZ in cancer. Cancer Lett. 527, 164–173 (2022).
Mok, J. W. & Choi, K. W. Modulation of Hippo signaling by Mnat9 N-acetyltransferase for normal growth and tumorigenesis in. Drosoph. Cell Death Dis. 13, 101 (2022).
Cho, Y. S. & Jiang, J. Hippo-independent regulation of Yki/Yap/Taz: a non-canonical view. Front. Cell Dev. Biol. 9, 658481 (2021).
Stepan, J., Anderzhanova, E. & Gassen, N. C. Hippo signaling: emerging pathway in stress-related psychiatric disorders? Front. Psychiatry 9, 715 (2018).
Sun, T. & Chi, J. T. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: the therapeutic implications. Genes Dis. 8, 241–249 (2021).
Reggiani, F., Gobbi, G., Ciarrocchi, A. & Sancisi, V. YAP and TAZ are not identical twins. Trends Biochem. Sci. 46, 154–168 (2021).
Abdi, K. & Kuo, C. T. Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev. 32, 740–741 (2018).
Buckley, C. E. & St Johnston, D. Apical–basal polarity and the control of epithelial form and function. Nat. Rev. Mol. Cell Biol. 23, 559–577 (2022).
Simons, M. & Mlodzik, M. Planar cell polarity signaling: from fly development to human disease. Annu. Rev. Genet. 42, 517–540 (2008).
Schroeder, M. C. & Halder, G. Regulation of the Hippo pathway by cell architecture and mechanical signals. Semin. Cell Dev. Biol. 23, 803–811 (2012).
Bretscher, A., Edwards, K. & Fehon, R. G. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3, 586–599 (2002).
Su, T., Ludwig, M. Z., Xu, J. & Fehon, R. G. Kibra and Merlin activate the Hippo pathway spatially distinct from and independent of expanded. Dev. Cell 40, 478–490e473 (2017).
Wei, Y. et al. NEDD4L-mediated Merlin ubiquitination facilitates Hippo pathway activation. EMBO Rep. 21, e50642–e50642 (2020).
Zhang, N. et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27–38 (2010).
Matsuda, T. et al. NF2 activates Hippo signaling and promotes ischemia/reperfusion injury in the heart. Circ. Res. 119, 596–606 (2016).
Ding, Y. et al. Hippo signaling suppresses tumor cell metastasis via a Yki-Src42A positive feedback loop. Cell Death Dis. 12, 1126 (2021).
Shen, H. et al. SCRIB promotes proliferation and metastasis by targeting Hippo/YAP signalling in colorectal cancer. Front. Cell Dev. Biol. 9, 656359–656359 (2021).
Varelas, X. et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. Dev. Cell 19, 831–844 (2010).
Wang, W., Huang, J. & Chen, J. Angiomotin-like proteins associate with and negatively regulate YAP1. J. Biol. Chem. 286, 4364–4370 (2011).
Hirate, Y. et al. Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos. Curr. Biol. 23, 1181–1194 (2013).
Mana-Capelli, S. & McCollum, D. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling. J. Biol. Chem. 293, 18230–18241 (2018).
Robinson, B. S. & Moberg, K. H. Cell–cell junctions: α-catenin and E-cadherin help fence in Yap1. Curr. Biol. 21, R890–R892 (2011).
Silvis, M. R. et al. α-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci. Signal. 4, ra33 (2011).
Beutel, O. et al. Phase separation of Zonula Occludens proteins drives formation of tight junctions. Cell 179, 923–936 (2019). e911.
Domínguez-Calderón, A. et al. ZO-2 silencing induces renal hypertrophy through a cell cycle mechanism and the activation of YAP and the mTOR pathway. Mol. Biol. Cell 27, 1581–1595 (2016).
Bryant, P. J. et al. Mutations at the fat locus interfere with cell proliferation control and epithelial morphogenesis in. Drosoph. Dev. Biol. 129, 541–554 (1988).
Mahoney, P. A. et al. The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell 67, 853–868 (1991).
Sopko, R. & McNeill, H. The skinny on fat: an enormous cadherin that regulates cell adhesion, tissue growth, and planar cell polarity. Curr. Opin. Cell Biol. 21, 717–723 (2009).
Lawrence, P. A., Struhl, G. & Casal, J. Do the protocadherins fat and Dachsous link up to determine both planar cell polarity and the dimensions of organs? Nat. Cell Biol. 10, 1379–1382 (2008).
Irvine, K. D. & Harvey, K. F. Control of organ growth by patterning and hippo signaling in. Drosoph. Cold Spring Harb. Perspect. Biol. 7, a019224 (2015).
Mao, Y. et al. Dachs: an unconventional myosin that functions downstream of fat to regulate growth, affinity and gene expression in. Drosoph. Dev. 133, 2539–2551 (2006).
Vrabioiu, A. M. & Struhl, G. Fat/Dachsous signaling promotes Drosophila wing growth by regulating the conformational state of the NDR kinase warts. Dev. Cell 35, 737–749 (2015).
Dasgupta, I. & McCollum, D. Control of cellular responses to mechanical cues through YAP/TAZ regulation. J. Biol. Chem. 294, 17693–17706 (2019).
Chakraborty, S. et al. Agrin as a mechanotransduction signal regulating YAP through the Hippo pathway. Cell Rep. 18, 2464–2479 (2017).
Li, Z. et al. Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis. Ann. Rheum. Dis. 80, 891–902 (2021).
Pereira, D. et al. Cell geometry and the cytoskeleton impact the nucleo-cytoplasmic localisation of the SMYD3 methyltransferase. Sci. Rep. 10, 20598 (2020).
Wada, K.-I. et al. Hippo pathway regulation by cell morphology and stress fibers. Development 138, 3907–3914 (2011).
Roux, E., Bougaran, P., Dufourcq, P. & Couffinhal, T. Fluid shear stress sensing by the endothelial layer. Front. Physiol. 11, 861 (2020).
Reichenbach, M. et al. Differential impact of fluid shear stress and YAP/TAZ on BMP/TGF-β Induced osteogenic target genes. Adv. Biol. 5, 2000051 (2021).
Lv, H. & Ai, D. Hippo/yes-associated protein signaling functions as a mechanotransducer in regulating vascular homeostasis. J. Mol. Cell. Cardiol. 162, 158–165 (2022).
Zhong, W. et al. Mesenchymal stem cell and chondrocyte fates in a multishear microdevice are regulated by Yes-associated protein. Stem Cells Dev. 22, 2083–2093 (2013).
Zhao, B. et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26, 54–68 (2012).
Ibar, C. et al. Tension-dependent regulation of mammalian Hippo signaling through LIMD1. J. Cell Sci. 131, jcs214700 (2018).
Rauskolb, C. et al. Cytoskeletal tension inhibits Hippo signaling through an Ajuba–Warts complex. Cell 158, 143–156 (2014).
Li, J. et al. Zipper-interacting protein kinase promotes epithelial-mesenchymal transition, invasion and metastasis through AKT and NF-kB signaling and is associated with metastasis and poor prognosis in gastric cancer patients. Oncotarget 6, 8323–8338 (2015).
Short, B. Integrin signaling tranquilizes Hippo. J. Cell Biol. 210, 364–364 (2015).
Zhu, B. et al. Piezo 1 activation facilitates cholangiocarcinoma metastasis via Hippo/YAP signaling axis. Mol. Ther. Nucleic Acids 24, 241–252 (2021).
Jiang, C. et al. Mechanochemical control of epidermal stem cell divisions by B-plexins. Nat. Commun. 12, 1308–1308 (2021).
Dobrokhotov, O., Samsonov, M., Sokabe, M. & Hirata, H. Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms. Clin. Transl. Med. 7, 23 (2018).
Dupont, S. Regulation of YAP/TAZ activity by mechanical cues: an experimental overview. Methods Mol. Biol. 1893, 183–202 (2019).
Gumbiner, B. M. & Kim, N.-G. The Hippo-YAP signaling pathway and contact inhibition of growth. J. Cell Sci. 127, 709–717 (2014).
Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747–2761 (2007).
Sharif, G. M. & Wellstein, A. Cell density regulates cancer metastasis via the Hippo pathway. Future Oncol. 11, 3253–3260 (2015).
Paul, A. et al. Cell adhesion molecule KIRREL1 is a feedback regulator of Hippo signaling recruiting SAV1 to cell-cell contact sites. Nat. Commun. 13, 930 (2022).
Gu, Y. et al. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers. Cell Rep. 40, 111296 (2022).
Wang, C. et al. Integrated screens uncover a cell surface tumor suppressor gene KIRREL involved in Hippo pathway. Proc. Natl Acad. Sci. USA 119, e2121779119 (2022).
Kim, N. G. & Gumbiner, B. M. Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity. Proc. Natl Acad. Sci. USA 116, 9877–9882 (2019).
Wu, J. et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature 572, 402–406 (2019).
Shalhout, S. Z. et al. YAP-dependent proliferation by a small molecule targeting annexin A2. Nat. Chem. Biol. 17, 767–775 (2021).
Ooki, T. et al. High-molecular-weight hyaluronan is a Hippo Pathway ligand directing cell density-dependent growth inhibition via PAR1b. Dev. Cell 49, 590–604 (2019). e599.
Meng, Z., Moroishi, T. & Guan, K.-L. Mechanisms of Hippo pathway regulation. Genes Dev. 30, 1–17 (2016).
Gurevich, E. V., Gainetdinov, R. R. & Gurevich, V. V. G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharm. Res. 111, 1–16 (2016).
Choi, K. M. et al. GPCR-mediated YAP/TAZ inactivation in fibroblasts via EPAC1/2, RAP2C, and MAP4K7. J. Cell Physiol. 236, 7759–7774 (2021).
Zindel, D. et al. G protein-coupled receptors can control the Hippo/YAP pathway through Gq signaling. FASEB J. 35, e21668 (2021).
Miller, E. et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem. Biol. 19, 955–962 (2012).
Zmajkovicova, K. et al. GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1. PLoS ONE 15, e0228195–e0228195 (2020).
Zhou, X. et al. Estrogen regulates Hippo signaling via GPER in breast cancer. J. Clin. Investig. 125, 2123–2135 (2015).
Wang, Z. et al. Endothelin promotes colorectal tumorigenesis by activating YAP/TAZ. Cancer Res. 77, 2413–2423 (2017).
Uemura, H. et al. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 66, 822–830 (2006).
Kim, H. B. et al. Prostaglandin E(2) activates YAP and a positive-signaling loop to promote colon regeneration after colitis but also carcinogenesis in mice. Gastroenterology 152, 616–630 (2017).
Gong, R. et al. Opposing roles of conventional and novel PKC isoforms in Hippo-YAP pathway regulation. Cell Res. 25, 985–988 (2015).
Yu, Z. et al. IL-17A promotes psoriasis-associated keratinocyte proliferation through ACT1-dependent activation of YAP–AREG axis. J. Investig. Dermatol. 142, 2343–2352 (2022).
Sorrentino, G. et al. Glucocorticoid receptor signalling activates YAP in breast cancer. Nat. Commun. 8, 14073 (2017).
Miranda, M. Z. et al. TGF-β1 regulates the expression and transcriptional activity of TAZ protein via a Smad3-independent, myocardin-related transcription factor-mediated mechanism. J. Biol. Chem. 292, 14902–14920 (2017).
Yao, M. et al. BMP2-SMAD signaling represses the proliferation of embryonic neural stem cells through YAP. J. Neurosci. 34, 12039–12048 (2014).
Taniguchi, K. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519, 57–62 (2015).
Zhou, X. et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. J. Hematol. Oncol. 13, 77 (2020).
Ando, T. et al. EGFR regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Commun. Biol. 4, 1237 (2021).
Wang, X. et al. YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis. Dev. Cell 42, 462–478e467 (2017).
Mao, B., Gao, Y., Bai, Y. & Yuan, Z. Hippo signaling in stress response and homeostasis maintenance. Acta Biochim. Biophys. Sin. 47, 2–9 (2014).
Zeybek, D. N., Baysal, E., Bozdemir, O. & Buber, E. Hippo signaling: a stress response pathway in stem cells. Curr. Stem Cell Res. Ther. 16, 824–839 (2021).
Yan, L., Cai, Q. & Xu, Y. Hypoxic conditions differentially regulate TAZ and YAP in cancer cells. Arch. Biochem. Biophys. 562, 31–36 (2014).
Ma, B. et al. Zyxin–Siah2–Lats2 axis mediates cooperation between Hippo and TGF-β signalling pathways. Nat. Commun. 7, 11123–11123 (2016).
Ma, B. et al. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat. Cell Biol. 17, 95–103 (2015).
Tao, E. W. et al. A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2. J. Exp. Clin. Cancer Res. 40, 67 (2021).
Howell, S. H. Endoplasmic reticulum stress responses in plants. Annu. Rev. Plant Biol. 64, 477–499 (2013).
Wu, H. et al. Integration of Hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis. Nat. Commun. 6, 6239 (2015).
Mo, J. S. et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol. 17, 500–510 (2015).
Wang, W. et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat. Cell Biol. 17, 490–499 (2015).
Hong, A. W. et al. Osmotic stress-induced phosphorylation by NLK at Ser128 activates YAP. EMBO Rep. 18, 72–86 (2017).
Hong, A. W. et al. Critical roles of phosphoinositides and NF2 in Hippo pathway regulation. Genes Dev. 34, 511–525 (2020).
Luo, M. et al. Heat stress activates YAP/TAZ to induce the heat shock transcriptome. Nat. Cell Biol. 22, 1447–1459 (2020).
Zhao, B. et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22, 1962–1971 (2008).
Neininger, A. C., Dai, X., Liu, Q. & Burnette, D. T. The Hippo pathway regulates density-dependent proliferation of iPSC-derived cardiac myocytes. Sci. Rep. 11, 17759 (2021).
Heallen, T. et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458–461 (2011).
Lin, Z. et al. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. Circ. Res. 116, 35–45 (2015).
Morikawa, Y. et al. Dystrophin–glycoprotein complex sequesters Yap to inhibit cardiomyocyte proliferation. Nature 547, 227–231 (2017).
Diez-Cuñado, M. et al. miRNAs that induce human cardiomyocyte proliferation converge on the Hippo pathway. Cell Rep. 23, 2168–2174 (2018).
Yuan, Y. et al. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity. Nat. Commun. 11, 1472 (2020).
Corley, S. M. et al. Plau and Tgfbr3 are YAP-regulated genes that promote keratinocyte proliferation. Cell Death Dis. 9, 1106 (2018).
Hasegawa, K. et al. YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation. J. Pathol. 253, 80–93 (2021).
Mi, W. et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene 34, 3095–3106 (2015).
Deng, Y. et al. A reciprocal regulatory loop between TAZ/YAP and G-protein Gαs regulates Schwann cell proliferation and myelination. Nat. Commun. 8, 15161 (2017).
Schlegelmilch, K. et al. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell 144, 782–795 (2011).
Yi, C. et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci. Signal. 6, ra77–ra77 (2013).
Hu, C. et al. The Hippo–YAP pathway regulates the proliferation of alveolar epithelial progenitors after acute lung injury. Cell Biol. Int. 43, 1174–1183 (2019).
Lin, C. et al. YAP is essential for mechanical force production and epithelial cell proliferation during lung branching morphogenesis. Elife 6, e21130 (2017).
Gao, T. et al. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. Gastroenterology 144, 1543–1553e1541 (2013).
Lange, A. W. et al. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. J. Mol. Cell Biol. 7, 35–47 (2015).
Lin, C., Yao, E. & Chuang, P. T. A conserved MST1/2–YAP axis mediates Hippo signaling during lung growth. Dev. Biol. 403, 101–113 (2015).
Szymaniak, A. D., Mahoney, J. E., Cardoso, W. V. & Varelas, X. Crumbs3-mediated polarity directs airway epithelial cell fate through the Hippo pathway effector Yap. Dev. Cell 34, 283–296 (2015).
Zhao, R. et al. Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. Dev. Cell 30, 151–165 (2014).
Nantie, L. B. et al. Lats1/2 inactivation reveals Hippo function in alveolar type I cell differentiation during lung transition to air breathing. Development 145, dev163105 (2018).
Jia, X. et al. YAP and Wnt3a independently promote AECIIs proliferation and differentiation by increasing nuclear β-catenin expression in experimental bronchopulmonary dysplasia. Int. J. Mol. Med. 47, 195–206 (2021).
Chen, T. H. et al. YAP promotes myogenic differentiation via the MEK5–ERK5 pathway. FASEB J. 31, 2963–2972 (2017).
Judson, R. N. et al. The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. J. Cell Sci. 125, 6009–6019 (2012).
Wang, L. et al. YAP/TAZ are required to suppress osteogenic differentiation of vascular smooth muscle cells. iScience 23, 101860 (2020).
Chen, Q. et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 28, 432–437 (2014).
McNeill, H. & Reginensi, A. Lats1/2 regulate Yap/Taz to control nephron progenitor epithelialization and inhibit myofibroblast formation. J. Am. Soc. Nephrol. 28, 852–861 (2017).
Fallah, S. & Beaulieu, J. F. Src family kinases inhibit differentiation of intestinal epithelial cells through the Hippo effector YAP1. Biol. Open 10, bio058904 (2021).
Yi, J. et al. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology 64, 1757–1772 (2016).
Wu, Z. & Guan, K. L. Hippo signaling in embryogenesis and development. Trends Biochem. Sci. 46, 51–63 (2021).
Nishioka, N. et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev. Cell 16, 398–410 (2009).
Ralston, A. et al. Gata3 regulates trophoblast development downstream of Tead4 and in parallel to Cdx2. Development 137, 395–403 (2010).
Frum, T., Watts, J. L. & Ralston, A. TEAD4, YAP1 and WWTR1 prevent the premature onset of pluripotency prior to the 16-cell stage. Development 146, dev179861 (2019).
Lorthongpanich, C. et al. Temporal reduction of LATS kinases in the early preimplantation embryo prevents ICM lineage differentiation. Genes Dev. 27, 1441–1446 (2013).
Cockburn, K., Biechele, S., Garner, J. & Rossant, J. The Hippo pathway member Nf2 is required for inner cell mass specification. Curr. Biol. 23, 1195–1201 (2013).
Morin-Kensicki, E. M. et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol. Cell. Biol. 26, 77–87 (2006).
Kim, J. et al. YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J. Clin. Investig. 127, 3441–3461 (2017).
von Gise, A. et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc. Natl Acad. Sci. USA 109, 2394–2399 (2012).
Mahoney, J. E. et al. The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. Dev. Cell 30, 137–150 (2014).
Reginensi, A. et al. Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet. 9, e1003380 (2013).
Reginensi, A. et al. A critical role for NF2 and the Hippo pathway in branching morphogenesis. Nat. Commun. 7, 12309 (2016).
Moya, I. M. & Halder, G. Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat. Rev. Mol. Cell Biol. 20, 211–226 (2019).
Rodrigues, M., Kosaric, N., Bonham, C. A. & Gurtner, G. C. Wound healing: a cellular perspective. Physiol. Rev. 99, 665–706 (2019).
Wang, Y., Yu, A. & Yu, F. X. The Hippo pathway in tissue homeostasis and regeneration. Protein Cell 8, 349–359 (2017).
Hong, A. W., Meng, Z. & Guan, K. L. The Hippo pathway in intestinal regeneration and disease. Nat. Rev. Gastroenterol. Hepatol. 13, 324–337 (2016).
Barry, E. R. et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106–110 (2013).
Cai, J. et al. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24, 2383–2388 (2010).
Gregorieff, A. et al. Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer. Nature 526, 715–718 (2015).
Azzolin, L. et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 158, 157–170 (2014).
Swiderska-Syn, M. et al. Hedgehog regulates yes-associated protein 1 in regenerating mouse liver. Hepatology 64, 232–244 (2016).
Oh, S. H. et al. Liver regeneration requires Yap1-TGFβ-dependent epithelial–mesenchymal transition in hepatocytes. J. Hepatol. 69, 359–367 (2018).
Fan, F. et al. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci. Transl. Med. 8, 352ra108 (2016).
Porrello, E. R. et al. Transient regenerative potential of the neonatal mouse heart. Science 331, 1078–1080 (2011).
Heallen, T. et al. Hippo signaling impedes adult heart regeneration. Development 140, 4683–4690 (2013).
Lin, Z. et al. Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ. Res. 115, 354–363 (2014).
Xin, M. et al. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci. Signal. 4, ra70 (2011).
Aharonov, A. et al. ERBB2 drives YAP activation and EMT-like processes during cardiac regeneration. Nat. Cell Biol. 22, 1346–1356 (2020).
Liu, Z. et al. MAPK-mediated YAP activation controls mechanical-tension-induced pulmonary alveolar regeneration. Cell Rep. 16, 1810–1819 (2016).
LaCanna, R. et al. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J. Clin. Investig. 129, 2107–2122 (2019).
Huang, Z. et al. YAP stabilizes SMAD1 and promotes BMP2-induced neocortical astrocytic differentiation. Development 143, 2398–2409 (2016).
Park, R. et al. Yap is required for ependymal integrity and is suppressed in LPA-induced hydrocephalus. Nat. Commun. 7, 10329 (2016).
Poitelon, Y. et al. YAP and TAZ control peripheral myelination and the expression of laminin receptors in Schwann cells. Nat. Neurosci. 19, 879–887 (2016).
Li, J. et al. Matrix stiffening by self-mineralizable guided bone regeneration. Acta Biomater. 125, 112–125 (2021).
Elbediwy, A. et al. Integrin signalling regulates YAP and TAZ to control skin homeostasis. Development 143, 1674–1687 (2016).
Zhang, H., Pasolli, H. A. & Fuchs, E. Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc. Natl Acad. Sci. USA 108, 2270–2275 (2011).
Totaro, A. et al. YAP/TAZ link cell mechanics to Notch signalling to control epidermal stem cell fate. Nat. Commun. 8, 15206 (2017).
Lee, M. J. et al. YAP and TAZ regulate skin wound healing. J. Investig. Dermatol. 134, 518–525 (2014).
Wang, D. et al. Vitamin D3 analogue facilitates epithelial wound healing through promoting epithelial–mesenchymal transition via the Hippo pathway. J. Dermatol. Sci. 100, 120–128 (2020).
Gao, Y. et al. Autophagy inhibition facilitates wound closure partially dependent on the YAP/IL-33 signaling in a mouse model of skin wound healing. FASEB J. 35, e21920 (2021).
Tapon, N. et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110, 467–478 (2002).
Justice, R. W. et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9, 534–546 (1995).
Xu, T. et al. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121, 1053–1063 (1995).
Hall, C. A. et al. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 70, 8517–8525 (2010).
Lu, L. et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl Acad. Sci. USA 107, 1437–1442 (2010).
Xia, H. et al. LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 21, 1233–1241 (2002).
Zhou, D. et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16, 425–438 (2009).
Yu, F. X. et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25, 822–830 (2014).
Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018).
Eder, N. et al. YAP1/TAZ drives ependymoma-like tumour formation in mice. Nat. Commun. 11, 2380 (2020).
Ammoun, S. & Hanemann, C. O. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat. Rev. Neurol. 7, 392–399 (2011).
Siddiqui, I. A. et al. Resveratrol nanoformulation for cancer prevention and therapy. Ann. N. Y. Acad. Sci. 1348, 20–31 (2015).
Martinez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669–680 (2021).
Zhang, X. et al. The role of YAP/TAZ activity in cancer metabolic reprogramming. Mol. Cancer 17, 134 (2018).
Ayob, A. Z. & Ramasamy, T. S. Cancer stem cells as key drivers of tumour progression. J. Biomed. Sci. 25, 20 (2018).
Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759–772 (2011).
Cheung, P. et al. Regenerative reprogramming of the intestinal stem cell state via Hippo signaling suppresses metastatic colorectal cancer. Cell Stem Cell 27, 590–604 (2020).
Ma, S. et al. Hippo signalling maintains ER expression and ER(+) breast cancer growth. Nature 591, E1–E10 (2021).
Cottini, F. et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat. Med. 20, 599–606 (2014).
Pearson, J. D. et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer Cell 39, 1115–1134 (2021). e1112.
Li, Z. et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol. Oncol. 9, 1091–1105 (2015).
Minoo, P. et al. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod. Pathol. 20, 331–338 (2007).
Takahashi, Y. et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin. Cancer Res. 11, 1380–1385 (2005).
Wang, Y. et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 101, 1279–1285 (2010).
Zheng, X. et al. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling. Mol. Cancer 18, 47 (2019).
Guo, P. D. et al. RARgamma downregulation contributes to colorectal tumorigenesis and metastasis by derepressing the Hippo-Yap pathway. Cancer Res. 76, 3813–3825 (2016).
He, B. P. et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol. Med. 12, 161–170 (2006).
Yates, L. R. et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 32, 169–184 (2017).
Hsu, P. C. et al. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. J. Cell. Mol. Med. 22, 3073–3085 (2018).
Mittal, V. Epithelial–mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. 13, 395–412 (2018).
Gao, Y. et al. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat. Commun. 5, 4629 (2014).
Ma, X. et al. Hippo signaling promotes JNK-dependent cell migration. Proc. Natl Acad. Sci. USA 114, 1934–1939 (2017).
Fan, H. et al. ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP. Genes Dev. 34, 1359–1372 (2020).
Cheng, Y. et al. LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling. J. Exp. Clin. Cancer Res. 37, 228 (2018).
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
Nguyen, C. D. K. & Yi, C. YAP/TAZ signaling and resistance to cancer therapy. Trends Cancer 5, 283–296 (2019).
Zeng, R. & Dong, J. The Hippo signaling pathway in drug resistance in cancer. Cancers (Basel) 13, 318 (2021).
Wu, Q. et al. YAP drives fate conversion and chemoresistance of small cell lung cancer. Sci. Adv. 7, eabg1850 (2021).
Qin, X. et al. Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells. Biochim Biophys. Acta Mol. Basis Dis. 1866, 165625 (2020).
Wang, X. et al. TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway. J. Exp. Clin. Cancer Res. 37, 27 (2018).
Touil, Y. et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin. Cancer Res. 20, 837–846 (2014).
Zhang, X. et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 30, 2810–2822 (2011).
Ren, A., Yan, G., You, B. & Sun, J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res. 68, 2266–2274 (2008).
Yao, W., Zhu, S., Li, P. & Zhang, S. Large tumor suppressor kinase 2 overexpression attenuates 5-FU-resistance in colorectal cancer via activating the JNK-MIEF1-mitochondrial division pathway. Cancer Cell Int. 19, 97 (2019).
Munoz-Galvan, S. et al. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Mol. Cancer 19, 7 (2020).
Panciera, T. et al. Induction of expandable tissue-specific stem/progenitor cells through transient expression of YAP/TAZ. Cell Stem Cell 19, 725–737 (2016).
Bukowski, K., Kciuk, M. & Kontek, R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 21, 3233 (2020).
Gujral, T. S. & Kirschner, M. W. Hippo pathway mediates resistance to cytotoxic drugs. Proc. Natl Acad. Sci. USA 114, E3729–E3738 (2017).
Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002–1014 (2021).
Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).
Wang, Z., Wu, Z., Liu, Y. & Han, W. New development in CAR-T cell therapy. J. Hematol. Oncol. 10, 53 (2017).
Shi, H. et al. Myeloid-derived suppressor cells: implications in the resistance of malignant tumors to T cell-based immunotherapy. Front. Cell Dev. Biol. 9, 707198 (2021).
Xiao, M. et al. Tumor-associated macrophages: critical players in drug resistance of breast cancer. Front. Immunol. 12, 799428 (2021).
Wang, G. et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6, 80–95 (2016).
Guo, X. et al. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 31, 247–259 (2017).
Proietti, I. et al. BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancers (Basel) 12, 1823 (2020).
Subbiah, V., Baik, C. & Kirkwood, J. M. Clinical development of BRAF plus MEK inhibitor combinations. Trends Cancer 6, 797–810 (2020).
Joung, J. et al. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature 548, 343–346 (2017).
Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
Kitajima, S. et al. Overcoming resistance to dual innate immune and MEK inhibition downstream of KRAS. Cancer Cell 34, 439–452 (2018).
Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47, 250–256 (2015).
Xu, W. et al. Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. Cell Biosci. 5, 7 (2015).
Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway. Cancer Cell 34, 893–905e898 (2018).
Muranen, T. et al. ERK and p38 MAPK activities determine sensitivity to PI3K/mTOR inhibition via regulation of MYC and YAP. Cancer Res. 76, 7168–7180 (2016).
Kim, J. Y. et al. Yap is essential for retinal progenitor cell cycle progression and RPE cell fate acquisition in the developing mouse eye. Dev. Biol. 419, 336–347 (2016).
Cabochette, P. et al. YAP controls retinal stem cell DNA replication timing and genomic stability. Elife 4, e08488 (2015).
Asaoka, Y. et al. The Hippo pathway controls a switch between retinal progenitor cell proliferation and photoreceptor cell differentiation in zebrafish. PLoS ONE 9, e97365 (2014).
Sakabe, M. et al. YAP/TAZ-CDC42 signaling regulates vascular tip cell migration. Proc. Natl Acad. Sci. USA 114, 10918–10923 (2017).
Lee, J. S., Park, H. W., Cho, K. J. & Lyu, J. Sestrin2 inhibits YAP activation and negatively regulates corneal epithelial cell proliferation. Exp. Mol. Med. 52, 951–962 (2020).
Hao, G. M. et al. The Hippo signaling pathway: a potential therapeutic target is reversed by a Chinese patent drug in rats with diabetic retinopathy. BMC Complement. Alter. Med. 17, 187 (2017).
Bokhovchuk, F. et al. Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson’s chorioretinal atrophy. FEBS J. 286, 2381–2398 (2019).
Matsumoto, H. et al. Mammalian STE20-like kinase 2, not kinase 1, mediates photoreceptor cell death during retinal detachment. Cell Death Dis. 5, e1269 (2014).
Lu, Q. et al. Heterozygous loss of Yap1 in mice causes progressive cataracts. Investig. Ophthalmol. Vis. Sci. 61, 21 (2020).
Yu, W. et al. VGLL4 plays a critical role in heart valve development and homeostasis. PLoS Genet. 15, e1007977 (2019).
Ciarambino, T., Menna, G., Sansone, G. & Giordano, M. Cardiomyopathies: an overview. Int. J. Mol. Sci. 22, 7722 (2021).
Wang, P. et al. The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy. Basic Res. Cardiol. 109, 435 (2014).
Chen, S. N. et al. The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ. Res. 114, 454–468 (2014).
Wu, W. et al. Activation of Hippo signaling pathway mediates mitochondria dysfunction and dilated cardiomyopathy in mice. Theranostics 11, 8993–9008 (2021).
Leach, J. P. et al. Hippo pathway deficiency reverses systolic heart failure after infarction. Nature 550, 260–264 (2017).
Ikeda, S. et al. Hippo deficiency leads to cardiac dysfunction accompanied by cardiomyocyte dedifferentiation during pressure overload. Circ. Res. 124, 292–305 (2019).
Wang, L. et al. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. Nature 540, 579–582 (2016).
Mia, M. M. et al. Loss of Yap/taz in cardiac fibroblasts attenuates adverse remodeling and improves cardiac function. Cardiovasc. Res. 118, 1785–1804 (2021).
Mitani, A. et al. Transcriptional coactivator with PDZ-binding motif is essential for normal alveolarization in mice. Am. J. Respir. Crit. Care Med. 180, 326–338 (2009).
Bertero, T. et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J. Clin. Investig. 126, 3313–3335 (2016).
Kudryashova, T. V. et al. HIPPO-integrin-linked kinase cross-talk controls self-sustaining proliferation and survival in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 194, 866–877 (2016).
Kudryashova, T. V. et al. Noncanonical HIPPO/MST signaling via BUB3 and FOXO drives pulmonary vascular cell growth and survival. Circ. Res. 130, 760–778 (2022).
Lv, Y. et al. YAP controls endothelial activation and vascular inflammation through TRAF6. Circ. Res. 123, 43–56 (2018).
Chen, Y. et al. YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF. Cell Death Differ. 26, 1832–1844 (2019).
Gokey, J. J. et al. Active epithelial Hippo signaling in idiopathic pulmonary fibrosis. JCI Insight 3, e98738 (2018).
Eckardt, K.-U. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382, 158–169 (2013).
Qian, X. et al. YAP mediates the interaction between the Hippo and PI3K/Akt pathways in mesangial cell proliferation in diabetic nephropathy. Acta Diabetol. 58, 47–62 (2021).
Chen, J. & Harris, R. C. Interaction of the EGF receptor and the Hippo pathway in the diabetic kidney. J. Am. Soc. Nephrol. 27, 1689–1700 (2016).
Cai, J. et al. A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease. Genes Dev. 32, 781–793 (2018).
Lee, E. J. et al. TAZ/Wnt-beta-catenin/c-MYC axis regulates cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 117, 29001–29012 (2020).
Xu, D. et al. Scribble influences cyst formation in autosomal-dominant polycystic kidney disease by regulating Hippo signaling pathway. FASEB J. 32, 4394–4407 (2018).
Xu, D. et al. KLF4 initiates sustained YAP activation to promote renal fibrosis in mice after ischemia-reperfusion kidney injury. Acta Pharm. Sin. 42, 436–450 (2021).
Anorga, S. et al. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype. FASEB J. 32, 2644–2657 (2018).
Xu, C. et al. Tubule-specific Mst1/2 deficiency induces CKD via YAP and non-YAP mechanisms. J. Am. Soc. Nephrol. 31, 946–961 (2020).
Hickman, R. A., O’Shea, S. A., Mehler, M. F. & Chung, W. K. Neurogenetic disorders across the lifespan: from aberrant development to degeneration. Nat. Rev. Neurol. 18, 117–124 (2022).
Gogia, N. et al. Hippo signaling: bridging the gap between cancer and neurodegenerative disorders. Neural Regen. Res. 16, 643–652 (2021).
Andreone, B. J., Larhammar, M. & Lewcock, J. W. Cell death and neurodegeneration. Cold Spring Harb. Perspect. Biol. 12, a036434 (2020).
Irwin, M. et al. A positive feedback loop of Hippo- and c-Jun-amino-terminal kinase signaling pathways regulates amyloid-beta-mediated neurodegeneration. Front. Cell Dev. Biol. 8, 117 (2020).
Gogia, N. et al. Inactivation of Hippo and cJun-N-terminal Kinase (JNK) signaling mitigate FUS mediated neurodegeneration in vivo. Neurobiol. Dis. 140, 104837 (2020).
Lee, J. K. et al. MST1 functions as a key modulator of neurodegeneration in a mouse model of ALS. Proc. Natl Acad. Sci. USA 110, 12066–12071 (2013).
Mao, Y. et al. Targeting TEAD/YAP-transcription-dependent necrosis, TRIAD, ameliorates Huntington’s disease pathology. Hum. Mol. Genet. 25, 4749–4770 (2016).
Yamanishi, E. et al. A novel form of necrosis, TRIAD, occurs in human Huntington’s disease. Acta Neuropathol. Commun. 5, 19 (2017).
Loforese, G. et al. Impaired liver regeneration in aged mice can be rescued by silencing Hippo core kinases MST1 and MST2. EMBO Mol. Med. 9, 46–60 (2017).
Mooring, M. et al. Hepatocyte stress increases expression of yes-associated protein and transcriptional coactivator with PDZ-binding motif in hepatocytes to promote parenchymal inflammation and fibrosis. Hepatology 71, 1813–1830 (2020).
Bou Saleh, M. et al. Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis. J. Hepatol. 75, 912–923 (2021).
Wang, X. et al. Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab. 24, 848–862 (2016).
Wang, X. et al. Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis. Cell Metab. 31, 969–986 (2020).
Mannaerts, I. et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J. Hepatol. 63, 679–688 (2015).
Qing, J. et al. Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis. J. Hepatol. 76, 394–406 (2022).
Liu, Y. et al. Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury. J. Hepatol. 71, 719–730 (2019).
Higashi, T., Friedman, S. L. & Hoshida, Y. Hepatic stellate cells as key target in liver fibrosis. Adv. Drug Deliv. Rev. 121, 27–42 (2017).
Fujita, T. & Narumiya, S. Roles of hepatic stellate cells in liver inflammation: a new perspective. Inflamm. Regen. 36, 1 (2016).
Du, K. et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology 154, 1465–1479 (2018). e1413.
Gonzalez-Navajas, J. M., Lee, J., David, M. & Raz, E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12, 125–135 (2012).
Chhabra, R., Ball, C., Chantrey, J. & Ganapathy, K. Differential innate immune responses induced by classical and variant infectious bronchitis viruses in specific pathogen free chicks. Dev. Comp. Immunol. 87, 16–23 (2018).
Wang, S. et al. YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKvarepsilon-mediated phosphorylation. Nat. Immunol. 18, 733–743 (2017).
He, T. S. et al. The Hippo signaling component LATS2 enhances innate immunity to inhibit HIV-1 infection through PQBP1–cGAS pathway. Cell Death Differ. 29, 192–205 (2022).
Zuo, Y. et al. LATS1 is a central signal transmitter for achieving full type-I interferon activity. Sci. Adv. 8, eabj3887 (2022).
Zhou, D. et al. The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naive T cells. Proc. Natl Acad. Sci. USA 105, 20321–20326 (2008).
Mou, F. et al. The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J. Exp. Med. 209, 741–759 (2012).
Bai, X. et al. Mst1 positively regulates B-cell receptor signaling via CD19 transcriptional levels. Blood Adv. 1, 219–230 (2016).
Yang, J., Sundrud, M. S., Skepner, J. & Yamagata, T. Targeting Th17 cells in autoimmune diseases. Trends Pharm. Sci. 35, 493–500 (2014).
Shi, H. et al. Hippo kinases Mst1 and Mst2 sense and amplify IL-2R-STAT5 signaling in regulatory T cells to establish stable regulatory activity. Immunity 49, 899–914 (2018).
Geng, J. et al. The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells. Nat. Immunol. 18, 800–812 (2017).
Nehme, N. T. et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 119, 3458–3468 (2012).
Johnson, R. & Halder, G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat. Rev. Drug Discov. 13, 63–79 (2014).
Barry, E. R., Simov, V., Valtingojer, I. & Venier, O. Recent therapeutic approaches to modulate the Hippo pathway in oncology and regenerative medicine. Cells 10, 2715 (2021).
Liu, Z. et al. Multifunctional nanohybrid based on porous silicon nanoparticles, gold nanoparticles, and acetalated dextran for liver regeneration and acute liver failure theranostics. Adv. Mater. 30, e1703393 (2018).
Schirmer, A. U. et al. Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer. Mol. Ther. 30, 485–500 (2022).
Triastuti, E. et al. Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU-MP-1, protects the heart against adverse effects during pressure overload. Br. J. Pharm. 176, 3956–3971 (2019).
Wu, Q. et al. Astrocytic YAP protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model through TGF-beta signaling. Theranostics 11, 8480–8499 (2021).
Bata, N. et al. Inhibitors of the Hippo pathway kinases STK3/MST2 and STK4/MST1 have utility for the treatment of acute myeloid leukemia. J. Med. Chem. 65, 1352–1369 (2022).
Kastan, N. et al. Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues. Nat. Commun. 12, 3100 (2021).
Liu, S. et al. Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction. Sci. Transl. Med. 13, eabd6892 (2021).
Song, S. et al. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol. Cancer Ther. 17, 443–454 (2018).
Morice, S. et al. The YAP/TEAD axis as a new therapeutic target in osteosarcoma: effect of verteporfin and CA3 on primary tumor growth. Cancers 12, 3847 (2020).
Crooke, S. T., Witztum, J. L., Bennett, C. F. & Baker, B. F. RNA-targeted therapeutics. Cell Metab. 27, 714–739 (2018).
Lihuang, L. et al. Targeted combination therapy for glioblastoma by co-delivery of doxorubicin, YAP-siRNA and gold nanorods. J. Mater. Sci. Technol. 63, 81–90 (2021).
Fitamant, J. et al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 10, 1692–1707 (2015).
Feng, Y. et al. YAP promotes ocular neovascularization by modifying PFKFB3-driven endothelial glycolysis. Angiogenesis 24, 489–504 (2021).
Liu-Chittenden, Y. et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300–1305 (2012).
Vigneswaran, K. et al. YAP/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma. Clin. Cancer Res. 27, 1553–1569 (2021).
Dai, M. et al. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy. Nat. Commun. 12, 3055 (2021).
Barrette, A. M. et al. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models. Neuro Oncol. 24, 694–707 (2022).
Ni, X. et al. YAP is essential for treg-mediated suppression of antitumor immunity. Cancer Discov. 8, 1026–1043 (2018).
Zhou, Y. et al. YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1–ROS–mTOR pathway. Cancer Cell Int. 19, 179 (2019).
Chen, J. et al. YAP activation in renal proximal tubule cells drives diabetic renal interstitial fibrogenesis. Diabetes 69, 2446–2457 (2020).
Jin, J. et al. Inhibition of yes-associated protein by verteporfin ameliorates unilateral ureteral obstruction-induced renal tubulointerstitial inflammation and fibrosis. Int. J. Mol. Sci. 21, 8184 (2020).
Chen, W. S., Cao, Z., Krishnan, C. & Panjwani, N. Verteporfin without light stimulation inhibits YAP activation in trabecular meshwork cells: Implications for glaucoma treatment. Biochem. Biophys. Res. Commun. 466, 221–225 (2015).
Li, T. Y. et al. Critical role of PAFR/YAP1 positive feedback loop in cardiac fibrosis. Acta Pharmacol. Sin. 43, 2862–2872 (2022).
Bottini, A. et al. PTPN14 phosphatase and YAP promote TGFbeta signalling in rheumatoid synoviocytes. Ann. Rheum. Dis. 78, 600–609 (2019).
Zhang, H. et al. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci. Signal. 8, ra98 (2015).
Maeda, T., Chapman, D. L. & Stewart, A. F. Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation. J. Biol. Chem. 277, 48889–48898 (2002).
Pobbati, A. V. et al. Structural and functional similarity between the Vgll1–TEAD and the YAP–TEAD complexes. Structure 20, 1135–1140 (2012).
Jiao, S. et al. VGLL4 targets a TCF4–TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer. Nat. Commun. 8, 14058 (2017).
Guan, X. & Fierke, C. A. Understanding protein palmitoylation: biological significance and enzymology. Sci. China Chem. 54, 1888–1897 (2011).
Chan, P. et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat. Chem. Biol. 12, 282–289 (2016).